Cloudbreak Pharma shares halted amid probe into ‘IPO rigging’
Just 14 months after its market debut, the drug developer is under investigation over regulatory concerns that its IPO demand was artificially inflated Key Takeaways: Cloudbreak’s IPO drew strong retail…
Eye drug maker VivaVision feels the strain in IPO funding dash
The developer of new treatments for ocular disorders is in a race against time to secure a Hong Kong listing before its cash reserves run out Key Takeaways: Two VivaVision…
Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
The developer of eye drugs has yet to launch a product on the market and could face financial pressure if its latest listing attempt falters Key Takeaways: Cloudbreak has sold…
RELATED ARTICLES
-
Cold-chain provider Shanghai Shengsheng joins pharma IPO hopefuls
- Investors pile onto TenNor IPO with hopes for new type of gastric drug
-
Montage forecasts strong profit growth as shares plunge on Korea probe
688008.SHG
-
Salubris refiles for Hong Kong IPO as generics lose steam
002294.SHE
- Insilico revenue soars above $100 million on AI drug partnerships
- A healthy return: drug spin-off nets Keymed up to $320 million
